[Clinical implications of thrombolytic therapy for patients with acute intermediate-high risk pulmonary embolism in Tibet plateau, China].

At present, clinical studies and case reports of systemic thrombolytic therapy for patients with acute pulmonary embolism in Tibet Plateau are very rare. There is little understanding of the risk factors, clinical characteristics, and thrombolytic therapy for patients with acute pulmonary embolism at intermediate-high risk in Tibet Plateau. In this paper, we reported the data of 4 patients with acute intermediate-high risk pulmonary embolism treated with thrombolytic therapy in Lhasa People's Hospital. The demographic characteristics, clinical manifestations, treatment, and outcomes were analyzed. We summarized the clinical features and raised scientific issues. We aimed to provide basic data to improve the standardized diagnosis and treatment of acute pulmonary embolism in plateau, and to point out the direction of future clinical research in this field.

Circular RNA circ_0103552 promotes the invasion and migration of thyroid carcinoma cells by sponging miR-127.

OBJECTIVE: The aim of this study was to examine the regulatory role of circ-0103552 in the procession of thyroid carcinoma (TC) and the related underlying mechanisms. PATIENTS AND METHODS: The tissues were obtained from 56 patients diagnosed with TC in our hospital. Nthy-ori3-1 cell line and TC cell lines (TPC-1, SW579, 8505C) were purchased from American Type Culture Collection (ATCC). Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was conducted to analyze the expression of circ-0103552 in TC tissues and cell lines. Inhibition of circ-0103552 was achieved by circ-0103552 siRNA. Dual-Luciferase report assay was performed to confirm the potential target miRNA of circ-0103552. The transwell assay and wound-healing assay were designed to examine the invasion and migration ability of TC cells, respectively. RESULTS: Circ-0103552 was detected to be upregulated in TC tissues, as well as in TC cell lines, including TPC-1, SW579, and 8505C. The knockdown of circ-0103552 significantly reduced the invasion and migration ability in TC cells. It was predicted using the circular RNA database that microRNA-127 (miR-127) was a target miRNA of circ-0103552, which was confirmed by the Dual-Luciferase assay. Further studies revealed that circ-0103552 was involved in the invasion and migration of TC by sponging miR-127. CONCLUSIONS: The present study demonstrated that circ-0103552 acts as a regulator in the invasion and migration of TC by sponging miR-127.

Epigallocatechin gallate enhances treatment efficacy of oral nifedipine against pregnancy-induced severe pre-eclampsia: A double-blind, randomized and placebo-controlled clinical study.

WHAT IS KNOWN AND OBJECTIVE: Oral nifedipine is commonly used to treat pre-eclampsia, one of the most severe complications during pregnancy, but its clinical efficacy is less than ideal. Epigallocatechin gallate (EGCG), a natural compound from green tea, could benefit cardiovascular health especially hypertension. We investigated the clinical efficacy of EGCG, when complemented with oral nifedipine, in treating pre-eclampsia. METHODS: A total of 350 pregnant women with severe pre-eclampsia were recruited and randomized to receive oral nifedipine, together with placebo (NIF+placebo) or EGCG (NIF+EGCG). The primary treatment outcome was the time needed to control blood pressure and interval time before a new hypertensive crisis, whereas the secondary treatment outcome was the number of treatment doses to effectively control blood pressure, maternal adverse effects and neonatal complications. RESULTS AND DISCUSSION: Comparing NIF+EGCG group to NIF+placebo group, the time needed to control blood pressure was significantly shorter (NIF+EGCG 31.2±16.7 minutes, NIF+placebo 45.3±21.9 minutes; 95% CI 9.7-18.5 minutes), whereas interval time before a new hypertensive crisis was significantly prolonged (NIF+EGCG 7.2±2.9 hours, NIF+placebo 4.1±3.7 hours; 95% CI 2.3-3.9 hours), and the number of treatment dosages needed to effectively control blood pressure was also lower. Between the two treatment groups, no differences in incidence rates of maternal adverse effects or neonatal complications were observed. WHAT IS NEW AND CONCLUSIONS: EGCG is both safe and effective in enhancing treatment efficacy of oral nifedipine against pregnancy-induced severe pre-eclampsia, but formal validation is required prior to its recommendation for use outside of clinical trials.

Oral nifedipine vs. intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia.

WHAT IS KNOWN AND OBJECTIVE: Pre-eclampsia is one of the most challenging diseases of pregnancy. Both nifedipine and labetalol have been used for treatment of pregnancy-induced severe pre-eclampsia. METHODS: In the present study, the efficacy and safety of oral nifedipine and intravenous labetalol for severe pre-eclampsia therapy were compared. Eligible pregnant women with severe pre-eclampsia (n = 147) were allocated to receive either oral nifedipine or intravenous labetalol. The primary endpoint of the study was the time needed to achieve target blood pressure. Secondary outcomes were the time interval before a new hypertensive crisis following effective blood pressure control, number of doses and adverse effects. RESULTS AND DISCUSSION: We found that the time taken to achieve effective blood pressure control was 35 vs. 42 min for oral nifedipine and intravenous labetalol, respectively (P = 0·37). Compared with labetalol group, no significant difference was observed regarding time interval and drug dosages in nifedipine arm. Moreover, no serious side effects on maternal or perinatal were observed in either group. WHAT IS NEW AND CONCLUSIONS: These findings suggest that both oral nifedipine and intravenous labetalol are effective for safely reducing blood pressure to target levels in patients with severe pre-eclampsia.